Immunocore Holdings plc (NASDAQ:IMCR) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET

Company Participants

Clayton Robertson - Head of IR

Bahija Jallal - CEO and Director

Brian Di Donato - CFO and Head of Strategy

Ralph Torbay - Head of Commercial

David Berman - Head of R&D

Mohammed Dar - CMO

Conference Call Participants

Michael Yee - Jefferies

Tyler Van Buren - TD Cowen

Justin Zelin - BTIG

Graig Suvannavejh - Mizuho

Justin Kim - Oppenheimer

Michael Schmidt - Guggenheim

Patrick Trucchio - H.C. Wainwright

Ahu Demir - Ladenburg Thalmann

Jeff Hung - Morgan Stanley

Gil Blum - Needham & Co.

Operator

Greetings. Welcome to the Immunocore Second Quarter 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

At this time, I would like to hand the call over to Clayton Robertson, Head of Investor Relations. Thank you. You may begin.

Clayton Robertson

Thank you. During today's call, we'll be making certain forward-looking statements including about financial projections, development activities, business strategy, and the timing and impact of future events. Actual results could differ materially from those projected by these statements, which are based on management's views as of today and subject to risks and uncertainties, including those noted in our most recent Form 20-F and any 6-Ks we filed with the SEC, in the earnings press release, we issued this morning. You are cautioned not to place undue reliance on these statements and Immunocore disclaims any obligation to update that. We'll also disclose certain non-IFRS measures on today's call which are reconciled to comparable IFRS measures in today's slides.

I will now hand over the call to our CEO, Dr. Bahija Jallal.

Bahija Jallal

Thank you, Clay. Good morning and good afternoon. Welcome everyone.

I'm here today with Brian Di Donato, our CFO; Ralph Torbay, Head of Commercial; David Berman, our Head of R&D; and Mohammed Dar, our CMO. We will answer your questions after my closing remarks.

During this call, we will share an overview of our second quarter and first half of the year performance, as we continue to deliver our mission to radically improve outcomes for patients with cancer, infectious disease, and autoimmune diseases. I am proud to report that we have delivered another excellent quarter of performance, both commercially and in terms of progress with our pipeline.